May 6, 2015 โ People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent ...
January 12, 2015 โ Daiichi Sankyo Co. Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ...
January 14, 2014 โ Daiichi Sankyo Company Ltd. announced results from the Phase 3 ENGAGE AF-TIMI 48 study [1]. The ...
December 6, 2012 โ Daiichi Sankyo Inc. and Eli Lilly and Co. announced results of two retrospective, observational ...
November 2, 2012 โ Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are ...
September 6, 2012 โ Daiichi Sankyo Co. Ltd. and Eli Lilly and Co. announced data from the TRILOGY ACS study, a phase III ...
The standard-of-care for dual antiplatelet therapy (DAPT) for more than a decade has been clopidogrel (Plavix) plus ...
January 23, 2012 โ A collection of real-life data from 5,000 atrial fibrillation (AF) patients across seven countries ...
August 18, 2011 โ The antiplatelet agent prasugrel (trade name Effient), in combination with aspirin, was associated ...
December 29, 2010 โ Patient enrollment has been completed for a Phase III trial of an oral Factor Xa inhibitor. The ...